Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 12/20 | 0.55 |
| ▸ | AURKA | O14965 | 5/20 | 0.49 |
| ▸ | PHGDH | O43175 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24409393 | 0.87 | RET (0.63) | RETAURKA | |
| SCHEMBL24409210 | 0.86 | RET (0.48) | RETAURKASYKAURKB | |
| SCHEMBL24409261 | 0.79 | RET (0.43) | RETAURKAAURKB | |
| SCHEMBL24409111 | 0.79 | RET (0.53) | RETAURKA | |
| SCHEMBL24409147 | 0.78 | RET (0.53) | RET | |
| SCHEMBL24409392 | 0.77 | RET (0.61) | RET | |
| SCHEMBL24409260 | 0.76 | RET (0.51) | RET | |
| SCHEMBL24409390 | 0.76 | RET (0.53) | RET | |
| SCHEMBL24409112 | 0.75 | RET (0.50) | RET | |
| SCHEMBL30630899 | 0.74 | RET (0.59) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | ELLIPSES PHARMA LTD (GB) | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144847-A1 | HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USE THEREOF | NOTUM, FURIN, CYP4A11 | RET 8/4885AURKA 4415/4885PHGDH 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.